Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lifei Tongluo mixture is a Traditional Chinese Medicine (TCM) hospital preparation developed by Tianjin Nankai Hospital, specifically indicated for the treatment of Mycoplasma pneumoniae pneumonia (MPP), particularly in pediatric patients. The formulation is designed based on the TCM therapeutic principles of clearing heat, transforming phlegm, and unblocking the collaterals to resolve blood stasis (清热化痰,活血通络). It is primarily utilized during the recovery or persistent stages of pneumonia to facilitate the absorption of pulmonary inflammatory exudates and prevent complications such as plastic bronchitis or permanent lung damage. Clinical studies indicate that the mixture effectively reduces systemic inflammatory markers, including Interleukin-6 (IL-6) and C-reactive protein (CRP), while improving hemorheological parameters like D-dimer levels, which are often elevated in severe cases of MPP.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lifei tongluo mixture.